Amgen

Founded in 1980 in Thousand Oaks, California, Amgen was one of the world's first biotechnology companies to industrialise the manufacture of proteins from living cells, a founding ambition that shaped modern biopharmaceuticals. Listed on Nasdaq under the ticker AMGN, Amgen has grown into one of the largest independent biotechnology companies globally, with operations spanning more than 100 countries and a workforce of tens of thousands.

Core Therapy Areas and Pipeline

Amgen's therapeutic focus covers oncology, haematology, cardiovascular disease, inflammation, bone health, and nephrology. The company's portfolio includes well-established products such as Enbrel for inflammatory conditions, Prolia and Xgeva for bone loss, and Repatha for cholesterol management. In oncology, its BiTE (bispecific T-cell engager) platform represents a distinctive approach to cancer immunotherapy, with Blincyto being one of the first approved BiTE molecules. The 2023 acquisition of Horizon Therapeutics expanded Amgen's rare disease capabilities, adding treatments for conditions such as thyroid eye disease and gout to its portfolio.

Manufacturing and Global Infrastructure

Amgen operates a substantial global manufacturing network, with large-scale biologics production facilities across the United States, Puerto Rico, Ireland, and Singapore. This internal manufacturing capability, built from the company's earliest years, gives Amgen end-to-end control over biologics production at commercial scale. The company has also invested in next-generation small molecule research alongside its biologics heritage, broadening its discovery toolkit.

With decades of published research, long-standing academic and clinical partnerships, and a pipeline extending across multiple therapeutic categories, Amgen remains a central reference point for practitioners, researchers, and industry professionals working in the global pharmaceutical and biotechnology sector.

Further information is available at amgen.com.